Physician profile
Allan Heller
NPI 1114196466
$132,116.76
in general payments reported to CMS, 2019-2025
9 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $13K · 2021: $12K · 2022: $17K · 2023: $22K · 2024: $52K · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $72K · Travel and Lodging: $1,139 · Food and Beverage: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $72,223.75 |
| Travel and Lodging | $1,138.63 |
| Food and Beverage | $247.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $72,223.75 | 2023-2024 | Waveform C, Mariner Midline, Mariner |
| Seaspine Orthopedics Corporation | $57,278.20 | 2019-2022 | |
| Alphatec Spine, INC | $1,138.63 | 2024 | Other - Miscellaneous |
| Centinel Spine, LLC | $1,000.00 | 2019 | |
| Innovasis INC | $190.19 | 2019-2023 | |
| Spineart USA INC | $159.68 | 2025 | Scarlet Al-T |
| Cerapedics INC. | $68.70 | 2019 | |
| Biocomposites INC | $30.56 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $27.05 | 2025 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.